Current CML therapy: progress and dilemma
- 23 May 2003
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 17 (6) , 1010-1012
- https://doi.org/10.1038/sj.leu.2402951
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyureaLeukemia, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemiaBlood, 2003
- Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1998
- Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 1997